Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

What Google DeepMind’s introduction of AlphaDev sorting algorithm could mean for drug discovery

By Brian Buntz | June 9, 2023

Logo of Google DeepMind is emerged as a key player in AI drug discoveryResearchers at Google’s DeepMind AI team have used AI to create advanced sorting algorithms, which although not specifically designed for drug discovery, could potentially benefit the field.

Published in Nature, DeepMind’s latest work demonstrates the use of deep reinforcement learning to create more efficient routines for sorting and hashing. These algorithms find use in various computational tasks, especially in computationally heavy processes such as drug discovery and simulations.

The researchers from DeepMind created an AI focused on code generation. To this end, they adapted the AlphaGo AI, a system known for defeating a human champion in the game of Go in 2016. The researchers created the AI system, known as AlphaDev, after staging a “game” approach, in which the AI treated a set of computer instructions like game moves. The AI then learned to “win” by sorting lists of three and five items as efficiently as possible. The resulting algorithm for the latter was 70% more efficient than current benchmarks.

While AlphaDev offers promise, DeepMind’s AlphaFold project has already begun to offer tangible benefits to drug discovery. Last year, we highlighted several ways the technology was finding use in life sciences.

AlphaFold’s impact on drug discovery and research

In an April conversation with Springer Nature, Pushmeet Kohli, the head of AI for Science at DeepMind, highlighted the potential of AlphaFold in protein folding to aid drug discovery. He stated, “That’s what we are seeing. It is supporting antibiotic resistance research. It is accelerating drug discovery.”

In recent years, AlphaFold has “emerged as the go-to tool in biology,” according to Kohli. He further explained that it enables “unrestricted access to every structure for both academic and commercial organizations, encompassing nearly 200 million proteins, which is essentially the entire protein universe. This has facilitated reaching every segment of the research community.”

Exploring potential drug discovery ramifications of AlphaDev

High-level illustration of what a sorting algorithm.

This Illustration shows what a sorting algorithm does. [Image courtesy of DeepMind]

The AlphaDev development could pave the way for drug discovery advances especially in situations involving massive troves of data. In particular, the AlphaDev algorithms could speed the process of sorting and comparing millions of potential small molecules, helping sift out the most promising candidates for lab experiments.

Given the inherent complexity and logistical challenges involved, drug discovery efficiency tends to resist advances. In fact, a report in the Future Journal of Pharmaceutical Sciences noted that cost and timelines have substantially increased over the past three decades.

But the field of AI in drug discovery continues to advance. In 2022, MIT researchers announced EquiBind, a geometric deep-learning model that speeds the process of identifying drug candidates. In particular, EquiBind yielded a 1,200-fold increase in speed compared to QuickVina2-W, a prominent computational molecular docking model.

DeepMind’s AlphaFold also promises to help researchers answer common questions. As Kohli explained, “From a sequence you have the structure, but what other proteins this protein will bind to? Which small molecules or drug would this protein interact with? What would happen if there’s a mutation in this protein?” The company’s AI can help unravel such questions by predicting protein structures based on their amino acid sequence. “There is a lot of work that is happening on taking sort of the structure produced by AlphaFold, and then trying to predict the function of that protein,” Kohli noted.

On a related note, EquiBind demonstrated its prowess in a technique known as “blind docking,” allowing it to directly predict the optimal ligand-to-protein binding configuration without knowing the protein’s target pocket beforehand. This capacity could accelerate the process of identifying viable drug-like molecules for specific protein targets.

Other recent AI advances in drug discovery

In 2021, MIT also announced a machine learning system known as DeepBAR that slashed the time taken to calculate the binding affinities between drug candidates and their targets.

Such breakthroughs promise to help the industry chip away at the decade-plus timeframes often involved in commercializing new drugs. The pace of implementing AI into drug discovery processes, however, may be gradual, as UBS recently noted in a report on generative AI in particular.

In terms of the AlphaDev algorithm, its performance improvements in specific computational tasks like sorting are unlikely to directly translate to broader tasks such as bioinformatics, genomics and molecular modeling, which involve a variety of algorithms and models. “I don’t think this problem of predicting the function has been solved. It’s not solved at all, completely, but it is a very active area of research,” Kohli added.


Filed Under: Data science, Drug Discovery, Drug Discovery and Development, machine learning and AI
Tagged With: AI in drug discovery, Antibiotic Resistance Research, Computational Molecular Docking, DeepMind AlphaDev, protein folding
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Abstract neural network
Inside IQVIA’s quest to build a multi-agent AI ‘dream team’ to transform clinical trials
Xaira and Verily co-founder ponders low-hanging fruit and blue-sky potential in FDA’s genAI rollout
Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE